Heron Therapeuti Stock Net Income
| HRTX Stock | USD 1.88 0.09 4.57% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Heron Therapeuti's long-term financial health and intrinsic value.
| Last Reported | Projected for Next Year | ||
| Net Loss | -13.6 M | -14.3 M | |
| Net Loss | -163.8 M | -172 M | |
| Net Loss | -13.6 M | -14.3 M | |
| Net Loss | (0.09) | (0.09) | |
| Net Income Per E B T | 0.85 | 0.92 |
Heron | Net Income | Build AI portfolio with Heron Stock |
Heron Therapeuti Company Net Income Analysis
Heron Therapeuti's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Heron Therapeuti Net Income | (13.58 M) |
Most of Heron Therapeuti's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Heron Therapeuti is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Heron Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Heron Therapeuti is extremely important. It helps to project a fair market value of Heron Stock properly, considering its historical fundamentals such as Net Income. Since Heron Therapeuti's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Heron Therapeuti's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Heron Therapeuti's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Heron Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Heron Therapeuti reported net income of (13.58 Million). This is 103.98% lower than that of the Biotechnology sector and 119.39% lower than that of the Health Care industry. The net income for all United States stocks is 102.38% higher than that of the company.
Heron Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Heron Therapeuti's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Heron Therapeuti could also be used in its relative valuation, which is a method of valuing Heron Therapeuti by comparing valuation metrics of similar companies.Heron Therapeuti is currently under evaluation in net income category among its peers.
Heron Therapeuti Institutional Holders
Institutional Holdings refers to the ownership stake in Heron Therapeuti that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Heron Therapeuti's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Heron Therapeuti's value.| Shares | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 2.8 M | Aigh Capital Management, Llc | 2025-03-31 | 2.8 M | Jw Asset Management, Llc | 2024-12-31 | 2.3 M | Renaissance Technologies Corp | 2025-03-31 | 2.3 M | Tang Capital Management Llc | 2024-12-31 | 2.1 M | Congress Park Capital Llc | 2025-03-31 | 2 M | Orchard Capital Management, Llc | 2024-12-31 | 1.9 M | Clearline Capital Lp | 2024-12-31 | 1.8 M | New York State Common Retirement Fund | 2025-03-31 | 1.8 M | Rubric Capital Management Lp | 2024-12-31 | 26.7 M | Blackrock Inc | 2025-03-31 | 8.6 M |
Heron Fundamentals
| Return On Equity | -24.09 | ||||
| Return On Asset | -0.0099 | ||||
| Profit Margin | (0.05) % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 427.13 M | ||||
| Shares Outstanding | 152.56 M | ||||
| Shares Owned By Insiders | 0.67 % | ||||
| Shares Owned By Institutions | 82.30 % | ||||
| Number Of Shares Shorted | 33.3 M | ||||
| Price To Earning | (5.15) X | ||||
| Price To Book | 12.60 X | ||||
| Price To Sales | 2.02 X | ||||
| Revenue | 144.28 M | ||||
| Gross Profit | 95.5 M | ||||
| EBITDA | (5.06 M) | ||||
| Net Income | (13.58 M) | ||||
| Cash And Equivalents | 83.54 M | ||||
| Cash Per Share | 0.81 X | ||||
| Total Debt | 177.76 M | ||||
| Debt To Equity | 6.64 % | ||||
| Current Ratio | 1.77 X | ||||
| Book Value Per Share | (0.19) X | ||||
| Cash Flow From Operations | (22.53 M) | ||||
| Short Ratio | 28.51 X | ||||
| Earnings Per Share | (0.05) X | ||||
| Price To Earnings To Growth | (0.18) X | ||||
| Target Price | 6.33 | ||||
| Number Of Employees | 122 | ||||
| Beta | 1.33 | ||||
| Market Capitalization | 300.55 M | ||||
| Total Asset | 233.15 M | ||||
| Retained Earnings | (1.92 B) | ||||
| Working Capital | 117.56 M | ||||
| Current Asset | 134.75 M | ||||
| Current Liabilities | 19.73 M | ||||
| Net Asset | 233.15 M |
About Heron Therapeuti Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Heron Therapeuti's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Heron Therapeuti using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Heron Therapeuti based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Heron Stock Analysis
When running Heron Therapeuti's price analysis, check to measure Heron Therapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heron Therapeuti is operating at the current time. Most of Heron Therapeuti's value examination focuses on studying past and present price action to predict the probability of Heron Therapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heron Therapeuti's price. Additionally, you may evaluate how the addition of Heron Therapeuti to your portfolios can decrease your overall portfolio volatility.